PALI-2108

PALI-2108

In Development for the Treatment of Moderate-to-Severe Ulcerative Colitis

PALI-2108 is a microbiota-activated PDE4 inhibitor prodrug being developed for the treatment of moderate-to-severe ulcerative colitis and is advancing toward the completion of IND-enabling studies and an IND filing.

Meets all the criteria of our Precision Delivery platform

  • Target not engaged until the parent drug is released from prodrug bioactivation at the site of inflammation
  • Low permeability in the upper GI tract
  • No premature prodrug bioactivation in the upper GI tract
  • Quantitative, enzyme-mediated parent release in the colonic area
Learn More About IBD and Ulcerative Colitis
Abdominal Adhesions are a Significant Medical Burden
Post Operative Bowel Function is a Big Bottleneck
  • Delayed bowel movement causes prolonged hospital stays and increased costs